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Background: Advanced squamous cervical cancer, one of the most commonly diagnosed cancers in women, still
remains a major problem in oncology due to treatment failure and distant metastasis. Antitumor therapy failure is
due to both intrinsic and acquired resistance; intrinsic resistance is often decisive for treatment response. In this
study, we investigated the specific pathways and molecules responsible for baseline therapy failure in locally
advanced squamous cervical cancer.
Methods: Twenty-one patients with locally advanced squamous cell carcinoma were enrolled in this study. Primary
biopsies harvested prior to therapy were analyzed for whole human gene expression (Agilent) based on the
patient’s 6 months clinical response. Ingenuity Pathway Analysis was used to investigate the altered molecular
function and canonical pathways between the responding and non-responding patients. The microarray results
were validated by qRT-PCR and immunohistochemistry. An additional set of 24 formalin-fixed paraffin-embedded
cervical cancer samples was used for independent validation of the proteins of interest.
Results: A 2859-gene signature was identified to distinguish between responder and non-responder patients.
‘DNA Replication, Recombination and Repair’ represented one of the most important mechanisms activated in
non-responsive cervical tumors, and the ‘Role of BRCA1 in DNA Damage Response’ was predicted to be the most
significantly altered canonical pathway involved in intrinsic resistance (p = 1.86E-04, ratio = 0.262). Immunohistological
staining confirmed increased expression of BRCA1, BRIP1, FANCD2 and RAD51 in non-responsive compared with
responsive advanced squamous cervical cancer, both in the initial set of 21 cervical cancer samples and the second set
of 24 samples.
Conclusions: Our findings suggest that FA/BRCA pathway plays an important role in treatment failure in advanced
cervical cancer. The assessment of FANCD2, RAD51, BRCA1 and BRIP1 nuclear proteins could provide important
information about the patients at risk for treatment failure.
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Table 1 Baseline characteristics of the patients in the
genomics study and IHC validation group
Characteristics Genomics study
group (n = 21)
IHC validation
group (n = 24)
Median age
(range), years
46 (27–73) 52 (28–62)
Median tumor
size (range), cm
5 (2–8) 4 (2–7)
Median hemoglobin
(range), g/dl
12.7 (7.9–14.4) 13.3 (10.2–14.9)
FIGO stage
II B 10 8
III A 5 11
III B 6 5
HPV subtype
HPV 16 16 19





*other high-risk in study group: 33,58,73.
other high-risk in validation group: 31,45,58.
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Cervical cancer, the third most commonly diagnosed can-
cer in women, with 529,800 cases in 2010 [1], represents a
major problem in oncology due to treatment failure and
distant metastasis. More than 85% of cervical cancers are
diagnosed every year in developing countries, and approxi-
mately 90% of overall deaths occur in these countries. If
detected at an early stage, cervical cancer represents one
of the most successfully treated cancers. Unfortunately,
because of the lack of screening programs in developing
countries, cervical cancer is predominantly detected in ad-
vanced stages (IIB-IIIB). About half of the patients with
advanced cervical cancer will develop recurrence or me-
tastasis in the first 2 years after completion of therapy.
Although new anticancer drugs are constantly being de-
veloped, overcoming drug resistance is still a challenge.
Therefore, there is an urgent need to identify new prog-
nostic factors that could distinguish between patients with
unfavorable prognoses from others with better prognoses.
Almost half of patients present baseline resistance (intrin-
sic resistance), and a large proportion of the remaining half
will develop resistance during treatment (acquired resist-
ance) [2]. Intrinsic resistance is often complex and occurs
through several mechanisms, depending on the therapy regi-
men. The treatment for pre-invasive lesions is generally
based on surgery; for invasive cervical cancers, the treatment
is based on surgery and/or radiation and cisplatin-based
chemotherapy [3]. The chemoradiotherapy treatment pro-
duces DNA double-strand breaks (DSBs), which is consid-
ered to be the most lethal form of DNA damage. DSBs are
caused by radiation and platinum compounds based chemo-
therapy but also could be produced by endogenous damage,
such as that caused by reactive oxygen species and collapsed
replication forks. DNA damage induces a series of molecular
responses that are responsible for the maintenance of gen-
ome integrity [4]. Deficiencies in DSB response and repair
could represent important events for intrinsic resistance.
The diagnosis of baseline resistance in individual pa-
tients could improve the cancer treatment by the avoid-
ance of inefficient therapy. Gene expression studies have
been conducted across many tumor types to investigate
the patterns of genes involved in intrinsic resistance. In
cervical cancer, relatively few studies have been focused on
identifying baseline resistance to chemoradiotherapy [5-7].
Therefore, the aim of our study was to investigate the spe-
cific pathways and molecules responsible for baseline ther-
apy failure in locally advanced squamous cervical cancer.
Methods
Sample collection
Patient samples and clinical data with end points were
obtained from the Departments of Radiotherapy and Path-
ology of The Oncology Institute ‘Prof. Dr. I. Chiricuta’,
Cluj-Napoca, Romania. This study was approved by theethics committee of The Oncology Institute ‘Prof. Dr. Ion
Chiricuta’. All patients gave informed consent in accor-
dance with the Declaration of Helsinki.
Twenty-one patients with locally advanced squamous cell
carcinoma (FIGO stage IIB-IIIB) were enrolled in the gen-
omics study. A tissue fragment from a primary biopsy and
a cervical lavage specimen were harvested from each pa-
tient prior to initiation of the therapy. Tissue samples were
stored in liquid nitrogen until use for RNA extraction.
Corresponding formalin-fixed paraffin-embedded (FFPE)
tissue samples were used for protein validation. Moreover,
an additional set of 24 FFPE samples was used for inde-
pendent immunohistochemistry validation of the data. All
patients in the validation and study groups had the same
including criteria. The clinical and histopathological charac-
teristics of the patients included in this study are presented
in Table 1.
The therapy schedule
The patients were treated with concomitant chemoradio-
therapy (CRT) associated or not with surgery. The radio-
therapy protocol includes external beam radiotherapy
(EBRT) to the pelvis delivered by a linear accelerator at
15MV for a dose of 46 Gy/23 fractions and a cervical
boost given by intracavitary high-dose-rate (HDR) brachy-
therapy (BT) in a dose of 10 Gy/2 fractions. Cisplatin was
administered concomitant with the radiotherapy as a
radiosensitizer. At this dose, patients were evaluated and,
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60 Gy concomitant with cisplatin and HDR BT until 20
Gy) or surgery (radical abdominal hysterectomy with
pelvic lymphadenectomy) was decided. In our internal
protocol, surgery was recommended, but not mandatory,
being a patient’s option. The tumor response was clinically
evaluated at 6 months after the end of the CRT treatment
and was defined as complete response (CR) or non-complete
response (NCR) (partial response and stable disease). For the
patients that underwent surgery, the histopathological evalu-
ation confirmed the clinical response.
RNA extraction and purification
Tumor sections with a minimum of 70% tumor cells
were harvested by macrodissection from primary biop-
sies of cervical cancers. Total RNA was extracted with
TriReagent (Sigma-Aldrich) and purified using an RNeasy
Mini kit (Qiagen) according to the manufacturer’s proto-
cols. Extracted RNA was assessed for quality with a Lab-
on-a-chip Bioanalyzer 2100 (Agilent Technologies). The
RNA Integrity Number (RIN) and rRNA 28S/18S ratio
were used to define the quality of the total RNA. The
RNAs with RINs >7.5 and rRNA 28S/18S ratios >1.8 were
used for further analysis. RNA concentrations were ad-
justed using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies).
HPV genotyping
Genomic DNA was extracted from 1 ml of cervical lav-
age using a High Pure DNA extraction kit (Roche). HPV
genotypes, including 37 high- and low-risk genotypes,
were identified with the Linear Array HPV Genotyping
Test (Roche) according to the manufacturer’s protocol.Oligonucleotide microarray technology
Agilent oligonucleotide technology was used to measure
gene expression changes in the samples of interest. Micro-
array probes (cRNA-Cy3) were synthesized from 200 ng of
total RNA in two reaction steps using a one-color Agilent
Low Input Quick Amp Labeling Kit according to the man-
ufacturer’s instructions. All labeled cRNAs (Cy3) were puri-
fied using an RNeasy Mini kit (Qiagen) and were evaluated
for quality control using a Nanodrop ND-1000 spectropho-
tometer. cRNAs with minimum yields of 1.65 μg and spe-
cific activities of 6 pmol/μl Cy3 per μg cRNA were selected
for further analysis. After fragmentation to an average size
of 60 – 100 nucleotides, each cRNA was hybridized for 17
hours at 65°C to whole-human-genome 4×44K microarray
slides (product G4112F; Agilent) following the manufac-
turer’s protocol (Agilent Technologies). The slides were
scanned with an Agilent G2505B US45102867 microarray
scanner, and gridding was performed with Feature Extrac-
tion Software v.10.5.1.1.The microarray data have been deposited in the NCBI
Gene Expression Omnibus (GEO) repository under ac-
cession number GSE56363.
Microarray data analysis
The microarray data, including median foreground and
background intensities, flags and feature annotations, were
imported into R/Bioconductor. The association between
log2 values of background and foreground intensities
across each array was estimated by computing Pearson
correlation coefficients. Suitable R packages (arrayQuality-
Metrics, limma, marray) were used for quality control,
normalization, filtering and data summarization. Between-
array normalization was performed using the quantile
normalization method. The median normalized signals
were used for further data analysis. To reduce the number
of non-informative features, the probes with saturated
and non-uniform signals present in more than 15% of the
samples were removed. Differentially expressed genes/se-
quences between non-responder and responder samples
were selected using the moderated t-statistic. This method
is an improvement over the standard t-statistic, as it allows
elimination of the influence of random small within-
group variance by sharing information across genes.
The Benjamini and Hochberg method was used to adjust the
p-values for multiple testing (adjusted p-value < 0.05). Only
genes/sequences with at least a 1.5-fold change in expression
between the studied groups were considered differentially
expressed. The hierarchical clustering using Euclidean dis-
tances and Ward method was further performed to cluster
the similarities in expression between genes/samples.
Functional analysis
The dataset containing differentially expressed genes was
uploaded into the Ingenuity Pathway Analysis (IPA) soft-
ware (Ingenuity® Systems, http://www.ingenuity.com) and
was associated with the biological functions and canonical
pathways in the Ingenuity Knowledge Base. Fisher’s exact
test (p < 0.05) was used to assess the significance of the as-
sociations between genes in the dataset and biological
functions or canonical pathways. In addition, for canonical
pathways, a ratio was computed between the number of
molecules from the dataset and the total number of mole-
cules in that pathway.
Quantitative real-time PCR (qRT-PCR)
The First Strand cDNA Synthesis Kit (Roche) was used to
reverse transcribe 200 ng of total RNA. Five microliters of
1:10 (v/v)-diluted cDNA was amplified in a final volume of
20 μl using a LightCycler 480 (Roche). The amplification
was performed with 1 μM specific primers (Tib Molbiol)
and a 0.2 μM specific hydrolysis probe from the Universal
Probe Library (UPL). The primers and UPL probes were
designed with Roche Applied Science software as follows:
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gtggaggagcaa (UPL#11); BRCA2 (NM_000059.3): F-agctta
ctccggccaaaaa, R-ttcctccaatgcttggtaaataa (UPL#50); RAD51
(NM_001164269.1): F-tgagggtacctttaggccaga, R-cactgccaga
gagaccatacc (UPL#66); FANCD2 (NM_033084.3): F-cgacttg
acccaaacttcct, R-tcctccaatctaatagacgacaact (UPL#9); BRIP1
(NM_032043.1): F-aatggcacttcatcaacttgtc, R-tggatgcctgtttc
ttagca (UPL#71); BLM (NM_000057.2): F-gatcagaaagcacca
cccata, R-tcagccatggtgtcacattc (UPL#34); and 18S rRNA
(NR_003286.2): F-gcaattattccccatgaacg, R- gggacttaatcaacg-
cacgc (UPL#48). Thermal cycling conditions were set as fol-
lows: activation at 95°C for 10 minutes; followed by 40
cycles of amplification, including denaturation at 95°C for
15 seconds, annealing at 55°C for 20 seconds and extension
at 72°C for 1 second; followed by a cooling step at 40°C for
30 seconds. The relative expression levels of target genes
(NCR vs. CR) were calculated using the ΔΔCt method [8]
after normalizing to 18S housekeeping gene.
Immunohistochemistry (IHC)
Immunohistochemistry was performed on FFPE 4-μm
thick tissue sections, using a standard protocol. Following
deparaffinization and rehydration of the tissue sections,
antigen retrieval was performed for 20 minutes in 0.01 M
citrate buffer (pH 6.0) using the boiling process (pressure
cooker). Endogenous peroxidase was blocked with H2O2
(3%). Blocking of the nonspecific reactions was performed
using the Novocastra Protein block™ solution. The sections
were incubated 30 minutes with primary antibodies at room
temperature in a humid chamber. The immunohistochemi-
cal staining was performed using the following dilutions for
the primary monoclonal antibodies: 1:400 for BRCA1 (Bio-
Vision Inc., OH, USA, clone#3364-100), 1:200 for BRCA2
(Covalab, Cambridge, UK, clone pab0457-0), 1:200 for
FANCD2 (Thermo Pierce Biotechnology Inc., IL, USA, clone
PA1-16548), 1:20 for Rad51 (Thermo Pierce Biotechnology
Inc., IL, USA, clone MA5-14416) and 1:300 for BPRIP1
(Abcam, Cambridge, UK, product number ab151509). Sec-
tions were sensitized using Post Primary Block™, and then in-
cubated with NovoLink™ polymer containing the secondary
antibody. The peroxidase reaction was developed using
diamino-benzidine tetrachloride (DAB) as chromogen. Sec-
tions were counterstained with hematoxylin.
The IHC staining was automatically assessed using the
ImmunoRatio free web-based application [9]. The applica-
tion is conceived for automated image analysis of immuno-
histochemical nuclear staining like estrogen receptor (ER),
progesterone receptor (PR), or Ki-67. Briefly, for every case 3
different representative images of immunostained sections
were taken using a CX41 Olympus microscope coupled with
a high resolution video camera AV5100M (MegaVideo IP
camera, Arecont Vision). The application performs the seg-
mentation of brown (DAB-colored), and hematoxylin-
stained nuclei, than calculates the labeling index as thepercentage of brown stained nuclear area over the total nu-
clear area. The system also produces a pseudo-colored re-
sult image, illustrating the area segmentation. Every
generated image was checked for consistency by two pa-
thologists (BR and SS). Only the correct segmented images
were accepted for further analysis.
Statistical methods
The follow-up endpoint for each patient represents a binary
evaluation of the treatment response at 6 months after the
end of the treatment. All existing factors were compared
when examining the two groups of patients (CR and NCR).
Categorical factors were analyzed using a chi-squared test,
and when reduced numbers of observations were present,
we applied Yates’ correction [10]. A comparison of medians
was performed using the median test and two-tailed un-
paired t test was used to evaluate for differences in gene ex-
pression between groups of interes (NCR vs CR). The
strengths of the association between genes of interest as well
as between PCR and microarray results were tested with a
Pearson parametric test. The receiver operating characteris-
tic (ROC) curve was used to evaluate the predictive accur-
acy of genes of interest in the differentiation between
samples with or without complete remission. [11]. The cal-
culation of the area under curve (AUC) and test equality
with a value of 0.5 was performed according to Bamber and
Hanley [12,13]. The point of optimal classification was con-
sidered the point nearest to (0.1) of the absolute classifica-
tion. Unpaired t-test on arcsine-transformed data was used
to determine whether the proportion of stained nuclear pro-
tein was different between non-responders and responders
samples, in both genomic and IHC validation groups.
All differences with p < 0.05 were considered statisti-
cally significant. The confidence intervals were evaluated
with the level of significance equal to 0.05.
Results
Patient and tumor characteristics
FIGO staging evaluation of the patients included in this
study revealed that approximately 48% of the patients
were in stage II, while the rest of 52% were in stage III.
Among these, 2 patients tested negative for HPV, whereas
HPV-16 subtype has been detected in the majority of the
cases. Based on 6 months treatment outcome evaluation
twelve patients presented complete remission and were
assigned to the CR group, while the rest of 9 patients that
partially responded or had stable disease were assigned to
the NCR group. We observed higher median age value in
the responders group (p < 0.01), however prognostic fac-
tors such as tumor size, hemoglobin and FIGO stage were
balanced between the NCR and CR groups (Table 2).
Since almost all the patients presented HPV 16-positive
tumors, the association between HPV subtype and treat-
ment outcome could not be assessed.
Table 2 Association between clinical and
histopathological data and treatment response
Characteristics No. of patients CR group NCR group p
n (%) n n
Study population 21 (100%) 12 9
Age (years)
Median 21 56.5 42 < 0.01
Range 28-73 27-55
Tumor size (cm)
Median 21 4.75 5 0.054
Range 2.0-6.5 2.5-8.0
Hemoglobin (g/dl)
Median 21 12.75 12.2 0.8
Range 7.9-14.2 10.1-14.4
FIGO stage
IIB 10 (47.62%) 4 6 0.62
IIIA 5 (23.81%) 4 1
IIIB 6 (28.57%) 4 2
HPV subtype
16 16 (76.19%) 10 6 -
Other high-risk 3 (14.29%) 1 2
Negative 2 (9.52%) 1 1
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Gene expression profiles for NCR and CR samples were
generated using one-color hybridization to whole hu-
man genome arrays carrying 43,376 biological se-
quences. We assessed the quality of the array before
and after normalization and we did not detect batch ef-
fects or outlier arrays. We observed a weak correlation
between background and foreground intensities across
each array (r range, 0.06 to 0.2), therefore we did not
perform background correction. To improve data qual-
ity, a filtering step was applied. A total number of
40,998 sequences passed the filtering criteria and were
used for further analysis. In class comparison analysis
we identified a signature of 2859 genes whose differential
expression in non-responder compared to responder sam-
ples exceeded 1.5-fold at an adjusted p-value < 0.05. Of
these, 1501 genes were up-regulated and 1358 genes were
down-regulated in NCR compared with CR.
To highlight the differences in gene expression a su-
pervised hierarchical clustering was performed on the
set of differentially expressed genes. Based on expression
profiles, non-responder and responder samples were
grouped in two distinct main clusters (Figure 1).Functional profile assessment
To obtain a global view of the altered biological functions
and canonical pathways that could be responsible forintrinsic resistance in cervical cancer, we performed func-
tional analysis in IPA. We chose to evaluate the biological
functions and canonical pathways because it provides more
robust results than studying individual genes. Sixty-five sig-
nificant molecular functions have been predicted in IPA
(p < 0.05) to be mediated by differentially expressed genes
identified in NCR vs. CR samples. ‘Cellular Movement’
(p = 5.30E-08-1.22E-02) was the top biological function
mediated by these genes followed by ‘Cell Cycle’ (p =
7.12E-07-1.22E-02) and ‘DNA Replication, Recombin-
ation and Repair’ (p = 7.12E-07-1.18E-02). The dataset
of differentially expressed genes were also integrated in
34 canonical pathways. The ‘Role of BRCA1 in DNA
Damage Response’ was predicted to be the most signifi-
cantly activated canonical pathway (p = 1.86E-04), which
suggests a baseline intrinsic resistance of non-responding
cervical cancer tumors. The top five molecular and cellu-
lar functions and the canonical pathways with associated
p-values are presented in Table 3.
It is known that cancer becomes resistant to therapy by
restoring the DNA repair machinery; therefore, we focused
our attention on the genes involved in ‘DNA Replication,
Recombination and Repair’ molecular mechanisms. In total,
124 genes from our dataset were listed in these mecha-
nisms (Additional file 1). The vast majority of genes (n =
92) were overexpressed with fold change between 1.503
and 2.867 while 32 genes were down-regulated (fold
change: −10.471 to −1.509) in NCR vs. CR cervical samples.
Among these genes, seventeen (RAD51, BRIP1, BLM,
BRCA1, BRCA2, BRCC3, HLTF, FANCD2, FANCI,
FANCM, FANCL, ATF1, E2F4, E2F2, SMARCA2,
SMARCA4 and RFC1) were significantly associated in IPA
with the ‘Role of BRCA1 in DNA Damage Response’ path-
way (p = 1.86E-04, ratio = 0.262) (Table 4). The overex-
pression of BRCA1, BRCA2, RAD51, BRIP1 (BACH1),
FANCD2, BLM and RFC in non-responding versus
responding cervical cancer samples suggests that DNA
repair mechanism activation occurs through cell cycle
arrest and homologous recombination (Figure 2).qRT-PCR validation of the microarray results
In order to assess the accuracy of microarray results, six
genes including RAD51, BRIP1 (BACH1), BRCA1,
BRCA2, BLM and FANCD2 involved in the ‘Role of
BRCA1 in DNA Damage Response’ pathway were se-
lected for validation by qRT-PCR. The fold changes cal-
culated between NCR vs. CR samples revealed at least
3-fold up-regulation for all genes of interest (Figure 3).
We assessed the correlation between the qRT-PCR and
microarray results by computing Pearson’s correlation
coefficients for each gene. A strong correlation between
the two methods was observed (r = 0.705 - 0.835)
(Table 5).
Figure 1 Heatmap of differentially expressed genes between CR (n = 9) and NCR (n = 12) samples obtained from supervised
hierarchical clustering using Euclidean distances and Ward method. The color indicates the level of mRNA expression: red - higher level of
expression, green - lower level of expression, black – no expression changes (each row represents a gene and each column represents a sample).
The CR samples were clustered together and clearly separated from NCR samples.
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involved in ‘Role of BRCA1 in DNA Damage Response’
pathway
We estimated the prognostic significance of the six se-
lected genes by the ROC analysis. We analyzed the ROC
curves for all previously known potential factors, including
age, tumor size, hemoglobin, along with our potentialmarkers: BRCA1, BRCA2, RAD51, FANCD2, BLM and
BRIP1. If the p-value was not significant (p > 0.05), then the
AUC, sensitivity, specificity and optimal classification point
were omitted. The investigated genes discriminated be-
tween the patients in the NCR and CR groups (p < 0.01)
suggesting a superior predictive value compared to classical
factors such as tumor size and hemoglobin. The summary
Table 3 The top significant molecular and cellular
functions identified by IPA
Molecular and cellular functions p value No. genes
Cellular movement 5.30E-08-1.22E-02 344








Canonical pathways p value Ratio
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six genes is presented in Table 6.
The correlations between the target genes BRCA1,
BRCA2, RAD51, FANCD2, BLM and BRIP1 indicated that
all genes were highly correlated with each other. The cor-
relation coefficients were between 0.69 (BRCA2 vs. BRIP1)
and 0.93 (BRCA1 vs. BRIP1) (Figure 4).Table 4 Genes involved in the “Role of BRCA1 in DNA Damag
from microarray experiment

















NM_003072 SMARCA4 −1,519IHC validation of the microarray results
Immunohistochemical staining was performed to obtain
further validation of microarray findings. We assessed the
protein expression of RAD51, BRIP1 (BACH1), BRCA1,
BRCA2, BLM and FANCD2 in all 21 samples used in the
genomic study (Figure 5). For BLM gene we did not iden-
tified a specific monoclonal antibody (MoAb), therefore
this gene could not be taken into account for protein val-
idation. An average percentage of nuclear staining on 3
different representative images of every sample was calcu-
lated for every protein of interest. We observed a signifi-
cantly increased protein levels of FANCD2, BRCA1,
RAD51 and BRIP1 in the nuclei of the NCR compared to
the CR cervical tumors. No difference was observed for
nuclear protein expression of BRCA2 in NCR compared
to CR tissues. A ratio between nuclear protein expressions
in NCR and CR groups was calculated (Table 7).
An additional set of 24 FFPE squamous cervical samples
(15 CR and 9 NCR) was used as an independent validation
of the protein data. Increased protein levels of FANCD2,
RAD51, BRCA1, and BRIP 1 (BACH1) in NCR compared
to CR cervical tumors groups were confirmed on the val-
idation set (Table 7).
Discussion
Cervical cancer continues to represent a major health prob-
lem for women from developing countries. Cervical cancer
lethality occurs because most patients are first diagnosed in
advanced stages. Even if early stages are successfully treated,e Response” pathway with associated p-values obtained
justed p-value Description
0,013 activating transcription factor 1
0,030 Bloom syndrome, RecQ helicase-like
0,008 breast cancer 1, early onset
0,011 breast cancer 2, early onset
0,016 BRCA1/BRCA2-containing complex, subunit 3
0,018 BRCA1 interacting protein C-terminal helicase 1
0,048 E2F transcription factor 2
0,013 E2F transcription factor 4, p107/p130-binding
0,010 Fanconi anemia, complementation group B
0,012 Fanconi anemia, complementation group D2
0,031 Fanconi anemia, complementation group L
0,005 Fanconi anemia, complementation group M
0,016 helicase-like transcription factor
0,010 RAD51 homolog (S. cerevisiae)
0,004 replication factor C (activator 1) 1, 145 kDa
0,041 SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily a, member 2
0,026 SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily a, member 4
Figure 2 Activation of the “Role of BRCA1 in DNA Damage Response’ pathways in NCR versus CR samples. Genes highlighted in red
were significantly overexpressed in non-responsive compared with responsive cervical cancers.
Balacescu et al. BMC Cancer 2014, 14:246 Page 8 of 14
http://www.biomedcentral.com/1471-2407/14/246advanced cervical cancer represents a major problem due
to increased rates of recurrence and distant metastasis. Al-
though knowledge about tumor biology and various mech-
anisms of resistance has increased in recent years, different
schedules of treatment, including new anticancer drugs,
have not efficiently reduced the occurrence of drug resist-
ance. Intrinsic resistance is often decisive for treatment fail-
ure; almost half of patients present with baseline resistance,
rendering classical therapies ineffective.
In an effort to elucidate the patterns of genes involved in
baseline resistance, we performed a genome-wide micro-
array assay on primary biopsies from patients with advanced
cervical cancers with known clinical and histological re-
sponses. All of the patients included in the study receivedradiotherapy as the main therapy and cisplatin as a radio-
sensitizer Based on the microarray analysis, we identified a
supervised gene expression profile that differed dramatically
between the non-responding and responding cervical tu-
mors. ‘DNA Replication, Recombination and Repair’
represents one of the most important molecular patterns
identified as important for intrinsic resistance in cervical
cancer. In our study, the non-responding cervical tumor
cells had more active DNA damage repair machinery than
responding cervical tumor cells, even before starting the
therapy. In total, 92 out of the 124 identified genes in-
volved in ‘DNA replication, recombination and repair’
were overexpressed in the non-responding tumors com-
pared with the responding tumors (Additional file 1).
Figure 3 qRT-PCR validation data for six genes (FANCD2, RAD51, BRCA2, BRCA1, BRIP1/BCH1 and BML) involved in the ‘Role of BRCA1
in DNA Damage Response’ pathway. Fold change was calculated using the ΔΔCt method relative to the CR group.
Table 6 ROC analysis for prognostic factors
Nr.crt. Variable AUC Classification
point
Sensitivity Specificity p
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DNA repair genes; therefore, we looked for pathways in-
volved in the maintenance of DNA stability. By classifying
the genes according to functional pathways, we identified
the ‘Role of BRCA1 in DNA Damage Response’ as the
most important canonical pathway involved in DNA re-
pair (Table 3). To our knowledge, there are no studies that
describe ‘Role of BRCA1 in DNA Damage Response’ path-
way as predictive for treatment outcome in cervical cancer,
even though a conserved pathway for increased DNA re-
pair mediated by BRCA1 was described for other patholo-
gies [14,15]. Among the genes significantly up-regulated in
the BRCA1 canonical pathway, we focused our attention
on a set of six genes that were considered of particular
interest: BRCA1, BRCA2, RAD51, FANCD2, BACH1/
BRIP1/FANCJ and BLM. The expression of these genes
detected by microarray was confirmed by qRT-PCR with
good correlation (Table 5).
Early studies on BRCA1 and BRCA2 have reveled that
both proteins are involved in DSB repair. In this study,Table 5 Pearson’s correlation coefficients of log2 fold
change values obtained from microarray and PCR
experiments
Gene Pearson coefficient p
BLM 0.835 < 0.0001
BRIP1 0.811 < 0.0001
BRCA1 0.765 < 0.0001
BRCA2 0.721 0.0002
RAD51 0.705 0.0005
FANCD2 0.759 < 0.0001we showed that BRCA1 and BRCA2 overexpression in pa-
tients with advanced cervical cancer is associated with
treatment failure. Several studies have pointed out that
BRCA-deficient cells are inefficient at repairing DNA dam-
age by homologous recombination (HR) [16,17] and are
thus more sensitive to chemotherapeutic drugs. Zhang
et al. [18] reported that the E6 and E7 HPV oncoproteins
interact with BRCA1 and alter its activity in cervical cancer
cells. However, the association between high-risk HPV ge-
notypes and treatment failure could not be evaluated in
our study as our sample set did not comprise a sufficient
number of other high-risk types. Recently, a so-called
BRCAness gene expression profile has also been correlated
with response to chemotherapy and outcome in patients
with epithelial ovarian cancer [19]. BRCA1 is a component
of the BASC complex that is important for efficient DNA1. BRCA1 0.81 <0.858565 0.92 0.78 <0.01
2. BRCA2 0.86 <0.602903 0.75 0.89 <0.01
3. RAD51 0.81 <0.895025 0.91 0.78 <0.01
4. FANCD2 0.84 <0.673616 0.83 0.78 <0.01
5. BLM 0.81 >0.871154 0.63 0.99 <0.01
6. BRIP1 0.81 >0.606256 0.78 0.75 <0.01
7. Age
(years)
0.86 >46 0.75 0.89 <0.01
8. Tumor
size (cm)
0.65 - - - 0.11
(NS)
9. Hb (g/dl) 0.64 - - - 0.39
(NS)
Figure 4 Pearson correlations between fold change values of the target genes.
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replication factor C (RFC) represent other important mem-
bers of the BASC complex [20].
Our microarray data pointed out an increased level of
BLM and RFC1 in the non-responding cervical cancers
compared with the responding cancers. Additionally, BRCA1
associates with the SWI/SNF chromatin-remodeling
complex and FANCD2 [21] and plays a role in regula-
ting the cellular localization of BACH1/BRIP1 (BRCA1-
associated carboxyl-terminal helicase). BRCA2 is also
involved in DNA repair; the protein interacts specific-
ally with RAD51, an essential protein involved in HR
[22]. In our efforts to understand the molecular basis of
treatment response in advanced cervical cancer, besides the
BRCA pathway, we also found the fanconi anemia (FA)
complementation group, FANCD2, FANCL, FANCM,
FANCJ/BRIP1/BACH and FANCI, to be involved in intrin-
sic resistance to chemo-radiotherapy. These FA proteins
are closely related to the BRCA1 and BRCA2 gene prod-
ucts and their partner proteins and are required for cellular
resistance to agents that cause DNA interstrand cross-links
(ICLs) [23]. The FANCD2 protein colocalizes to nuclear
foci together with BRCA1, BRCA2 and RAD51 and initi-
ates homology-directed DNA repair in a “FA/BRCApathway,’ both in response to DNA-damaging agents (cis-
platin, ionizing radiation, hydroxyurea, etc.) and in the ab-
sence of exogenous DNA damage during the S phase of the
cell cycle [24].
Our results revealed an increased protein level of
FANCD2, RAD51, BRCA1 and BRIP1 in the NCR com-
pared to CR cervical tumor nuclei. These observations
were also confirmed on an independent validation set, em-
phasizing the role of these four proteins in CRT resistance
(Table 7). Although we observed a 3.8-fold increase in
BRCA2 mRNA in NCR vs. CR cervical samples (qRT-PCR
data), there was no significant difference for BRCA2 pro-
tein between NCR and CR groups, which could be due to
either using an inadequate monoclonal antibody clone or
posttranscriptional modifications of the BRCA2 transcript.
A central step in the FA/BRCA pathway is the monoubi-
quitylation of FANCD2 and its translocation to chromatin
at the site of DNA damage [25]. The ubiquitylation of
FANCD2 is initiated by FANCM and is mediated by the
UBE2T (E2) enzyme and a multisubunit ubiquitin E3 ligase
that consists of eight FA proteins (FANCA/B/C/E/F/G/L/
M) [26]. FANCD2 can also be monoubiquitylated and
chromatin-loaded by the E3 ubiquitin ligase activity of
RAD18 in a FA-independent manner [27].
Figure 5 Validation of FANCD2 (A-B), RAD51 (C-D), BRCA1 (E-F), BRCA2 (G-H) and BRIP1 (I-J) protein expression in advanced squamous
cervical tumor cells. Staining for FANCD2, RAD51, BRCA1 and BRIP1 for the NCR cervical samples indicated strongly positive protein expression
compared with the CR cervical samples. The BRCA2 protein expression was comparable between the NCR and CR cervical samples;
(x200 magnification).
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RAD18 mRNA was observed in NCR compared to CR
cervical tumor samples (Additional file 1). We also ob-
served a slight increase in SLX4/FANCP/BTBD12 mRNA
(fold change = 1.3, p = 0.035) for the NCR vs. CR cervical
samples. SLX4 is a novel member of the FA genes that co-
ordinates multiple DNA repair pathways by acting as a
scaffold for multiple nucleases involved in ICL repair and
the mechanisms involved in HR [28]. Depletion of SLX4leads to hypersensitivity to cisplatin and reduced efficiency
of HR repair [29]. Narayan et al. [30] showed that advanced
cervical cancer is associated with alterations in the FA/
BRCA pathway by either promoter hypermethylation and/
or deregulated gene expression compared with the normal
cervix. FA inhibitors were recently proposed as important
tools for overcoming cisplatin resistance in tumors [31].
RAD51, one of the key molecules of DNA repair, is an-
other gene we found to be significantly overexpressed in
Table 7 Assessment of the nuclear proteins including
FANCD2, RAD51, BRCA2, BRCA1, BRIP1(BACH1) in NCR
and CR cervical tumors evaluated both for genomics
study set (n = 21) and IHC validation set (n = 24)
Proteins Cellular
localization
NCR % CR % NCR/CR ratio p-value
Genomics study
set (n = 21)
FANCD2 nucleus 32.53 15.6 2.09 0.032
RAD51 nucleus 14.88 7.11 2.09 0.016
BRCA2 nucleus 21.11 20.81 1.01 0.868
BRCA1 nucleus 27.78 10.69 2.60 0.032
BRIP1 (BACH1) nucleus 40.44 10.05 4.02 0.001
IHC validation
set (n = 24)
FANCD2 nucleus 25.34 16.22 1.56 0.011
RAD51 nucleus 16.87 4.86 3.47 0.000
BRCA1 nucleus 27.59 12.97 2.13 0.000
BRIP1 (BACH1) nucleus 30.73 14.55 2.11 0.011
The p-values in the bold format are statistically significant.
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http://www.biomedcentral.com/1471-2407/14/246the NCR cervical cancers. We observed a 3.4-fold increase
in RAD51 mRNA (qRT-PCR data) and also an increased
protein expression of RAD51 in the nuclei of the NCR vs.
CR cervical cancers. RAD51 has anti-apoptotic activity in
tumor cells [32], and high expression of this protein is cor-
related with poor prognosis, resistance to ionizing radiation
and drug resistance [33]. RAD51 is essential in the HR
process of DNA repair, its expression being tightly con-
trolled in normal healthy cells to maintain genomic stabil-
ity [34]. RAD51 co-localizes with BRCA1 and FANCD2 in
S-phase specific nuclear foci and initiates homology-driven
repair activity. Several studies have shown that in cancer
cells, this molecule is overexpressed, leading to radio- and
chemoresistance [35,36]. Elevated levels of RAD51 have been
associated with increased invasiveness in breast cancer pa-
tients [37] and have been demonstrated to be an independ-
ent prognostic marker of survival in non-small cell lung
cancer patients [38]. A previous microarray study of paired
cervical tumor samples (pre- and post-chemoradiotherapy)
reported down-regulation of RAD51 after treatment [5], sup-
porting the hypothesis that radiation sensitivity is facilitated
by a diminished DNA repair response. Targeting strategies
against this gene have been developed as possible anticancer
treatments; attempts to inhibit RAD51 have proven to
be successful in reducing treatment resistance in tumor
cells [39,40].
In a previous study, it was shown that poly(ADP-ribose)
polymerase (PARP) inhibitors could suppress the expres-
sion of BRCA1 and RAD51 [41]. The PARP family, espe-
cially PARP1 and PARP2, functions as DNA damage
sensors and recruits a variety of DNA repair proteins to
the site of damaged DNA [42]. In BRCA-positive breast
cancer, PARP inhibitors were found to increase thecytotoxic effects of radiation and chemotherapy based on
the principle of synthetic lethality [43]. In our microarray
study, we noted a higher level of PARP2 mRNA in the
NCR vs. CR cervical cancer samples (Additional file 1).
Previous studies have shown that prognostic factors
including younger age [44], tumor size [45], anemia
(hemoglobin) and FIGO stage [46], are used to estimate
overall survival, disease-free survival and local control in
cervical cancer. Nevertheless, they not provide information
about the baseline resistance and the tumor heterogeneity.
Our data indicates age as significant factor for treatment
response, however the sample size is limited and no final
conclusions can be drawn. Taking into account our find-
ings and the need to identify new valuable prognostic fac-
tors for baseline resistance, we suggest that if our results
are confirmed on a larger study, the assessment of nuclear
expression of FANCD2, RAD51, BRCA1 and BRIP1 pro-
teins could represent a supplementary prognostic factor
that would better tailor the treatment for patients with ad-
vanced cervical cancer. These results could be the founda-
tion for the development of new targeting strategies to
improve cervical cancer outcome.
Conclusions
Our data revealed high DNA repair machinery activity even
before starting radio-chemotherapy in NCR patients com-
pared with CR patients. Therefore, our findings demon-
strate that baseline FANCD2, RAD51, BRCA1 and BRIP1
nuclear protein expression could have an important role in
treatment failure in advanced squamous cervical cancer. To
our knowledge, this is the first study to demonstrate the
role of the FA/BRCA pathway in baseline resistance and
therapy failure in locally advanced cervical cancer.
Limitations
The limitation of this study is related to the small number
of samples even if we used an independent validation set
for protein data to increased confidence of these findings.
Larger studies have to confirm that the assessment of
these proteins could represent an important prognostic
factor that determines poor response to radiation and
chemotherapy for locally-advanced cervical cancers.
Additional file
Additional file 1: Genes involved in DNA replication,
recombination, and repair mechanisms.
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